Inspection Readiness

FDA to Begin Unannounced Inspections of Non-U.S. Manufacturing Facilities

Beginning August 2025, FDA inspections at non-U.S. manufacturing sites will take place without advance notice. This shift eliminates prior warning and signals a new standard for global regulatory oversight—one that demands continuous readiness.

With deep FDA expertise and regulatory professionals positioned around the world, ProPharma helps pharmaceutical, biotechnology, and medical device companies build and sustain inspection readiness—before the FDA arrives.

Inspection Readiness is not an option – now, more than ever, it is urgent.

We ensure that every step towards Inspection Readiness is carefully calibrated to your needs. Our method is backed by tangible tools and training programs developed from the ground up, tailored not just to your product, but to your organization's unique scale and scope. This approach allows you to maintain focus on running your business, while we dedicate ourselves fully to your Inspection Readiness, making it our singular priority.

Contact Us Today

Our team of experts are equipped to guide you through every step of any inspection your firm is facing, with experience and expertise. The overview below outlines how ProPharma supports clients through every stage of the inspection readiness lifecycle.

inspection-readiness-workflow-illustration

 

Inspection Readiness Experts

Unannounced inspections are coming. Preparation can't wait.

With global regulatory and quality expertise and a history of guiding clients through successful FDA inspections, ProPharma helps ensure your operations are always inspection ready—no matter when the FDA arrives.

Secure Your Regulatory Inspection Success

On average a new product takes approximately 10-15 years to develop, whether it is a biologic, a pharmaceutical product, a medical device, or a combination thereof.

  • Can you risk the time and resources you invested in development by ignoring the importance of Inspection Readiness for a new product?
  • Can you risk having an existing product off the market for remediation activities following a For Cause Inspection?
  • Can your patients?

ProPharma's expertise covers all aspects of Inspections. Inspection Readiness Evaluation, Project Management, your Inspection Program/Process, Logistics, and Training – are just some of the most important areas of Inspection Readiness. Our expertise can become your greatest asset. We are eager to become your partner in navigating this critical process.

Group of business professionals working at a conference table with laptops and clipboards
Group of medical professionals smiling in a common area

PAI Readiness

Pre-approval Inspections are one of the most critical inspections any Biologic, Pharmaceutical or Medical Device firm will undertake. Failure to meet FDA expectations can have a huge impact on organizations, including:

  • Delays to product launch.
  • Thousands, if not millions of dollars, in remediation costs.
  • Lost market share.
  • Loss of a firm's credibility.

PAI readiness is critical, and ProPharma is an industry leader in providing PAI Readiness to our clients.

BIMO Readiness

BIMO inspection readiness is essential for sponsors to ensure compliance with FDA regulations, protect data integrity, and uphold patient safety standards. By preparing thoroughly, sponsors:

  • Ensure compliance with FDA regulations.
  • Protect data integrity.
  • Uphold patient safety standards.
  • Help avoid costly delays.
  • Prevent potential compliance issues.
  • Facilitate smoother FDA inspections.
Healthcare provider looking into medical device

To date, we have had a 100% success rate on PAI Readiness projects for our clients

News & Insights

FDA's Shift to One Pivotal Trial for Drug Approval: Regulatory Strategy Implications for Sponsors

February 24, 2026

FDA's Shift to One Pivotal Trial for Drug Approval: Regulatory Strategy Implicat...

FDA’s shift to one pivotal trial raises global stakes. Learn how to engineer globally acceptable development programs from the start.

User Requirements for AI in GxP: Designing, Selecting, and Validating AI/ML Software with Confidence

February 23, 2026

User Requirements for AI in GxP: Designing, Selecting, and Validating AI/ML Soft...

Effective AI/ML implementation in life sciences requires clear user requirements, robust validation, and strong governance to ensure compliance and performance.

Why Medical Information Is Central to MAH Compliance, Access, and Patient Safety – Identifying Reportable Information

February 19, 2026

Why Medical Information Is Central to MAH Compliance, Access, and Patient Safety...

Learn why Medical Information is essential for MAH compliance, patient safety, and capturing reportable data, ensuring trust and proactive insights in real-world medical use.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

December 4, 2025

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

ProPharma taps Daniel Ryan as President of Clinical Research Solutions, strengthening its clinical trial management leadership and expanding its FSP Solutions.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Setting up a Global PV System - ProPharma

February 5, 2026

Setting up a Global PV System

A company needed to rapidly establish a fully compliant global pharmacovigilance (PV) system, including UK/EU QPPV coverage, to meet regulatory requirements by a fixed deadline. With safety data and...

Case Study High-Volume Global Pharmacovigilance Onboarding - ProPharma

January 30, 2026

High-Volume Global Pharmacovigilance Onboarding

A global biotechnology sponsor faced a sudden surge in pharmacovigilance demand, with monthly ICSR volumes exceeding 30,000 cases across multiple regions. Limited internal capacity, tight onboarding...

Case Study Stabilizing High-Volume Legal Case Processing Through Structured Governance - ProPharma

January 28, 2026

Stabilizing High-Volume Legal Case Processing Through Structured Governance

ProPharma’s client faced escalating operational risk as high-volume legal case documentation overwhelmed their prior vendor. Thousands of documents, missed regulatory timelines, and a surge of...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

News & Insights

FDA's Shift to One Pivotal Trial for Drug Approval: Regulatory Strategy Implications for Sponsors

February 24, 2026

FDA's Shift to One Pivotal Trial for Drug Approval: Regulatory Strategy Implicat...

FDA’s shift to one pivotal trial raises global stakes. Learn how to engineer globally acceptable development programs from the start.

User Requirements for AI in GxP: Designing, Selecting, and Validating AI/ML Software with Confidence

February 23, 2026

User Requirements for AI in GxP: Designing, Selecting, and Validating AI/ML Soft...

Effective AI/ML implementation in life sciences requires clear user requirements, robust validation, and strong governance to ensure compliance and performance.

Why Medical Information Is Central to MAH Compliance, Access, and Patient Safety – Identifying Reportable Information

February 19, 2026

Why Medical Information Is Central to MAH Compliance, Access, and Patient Safety...

Learn why Medical Information is essential for MAH compliance, patient safety, and capturing reportable data, ensuring trust and proactive insights in real-world medical use.

Previous Post Arrow Next Post Arrow
ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Expands Operations with New Office in Hyderabad

December 11, 2025

ProPharma Expands Operations with New Office in Hyderabad

ProPharma expands with a new office in Hyderabad, enhancing innovation and growth in regulatory, clinical, and compliance services for the life sciences industry.

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

December 4, 2025

ProPharma Welcomes Dan Ryan as President of Clinical Research Solutions

ProPharma taps Daniel Ryan as President of Clinical Research Solutions, strengthening its clinical trial management leadership and expanding its FSP Solutions.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Setting up a Global PV System - ProPharma

February 5, 2026

Setting up a Global PV System

A company needed to rapidly establish a fully compliant global pharmacovigilance (PV) system, including UK/EU QPPV coverage, to meet regulatory requirements by a fixed deadline. With safety data and...

Case Study High-Volume Global Pharmacovigilance Onboarding - ProPharma

January 30, 2026

High-Volume Global Pharmacovigilance Onboarding

A global biotechnology sponsor faced a sudden surge in pharmacovigilance demand, with monthly ICSR volumes exceeding 30,000 cases across multiple regions. Limited internal capacity, tight onboarding...

Case Study Stabilizing High-Volume Legal Case Processing Through Structured Governance - ProPharma

January 28, 2026

Stabilizing High-Volume Legal Case Processing Through Structured Governance

ProPharma’s client faced escalating operational risk as high-volume legal case documentation overwhelmed their prior vendor. Thousands of documents, missed regulatory timelines, and a surge of...

Previous Resource Arrow Next Resource Arrow
Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

March 12, 2026

Mastering the PSMF: The Pillar of Inspection Readiness for MAHs, LPPVs & QPPVs

Uncover the intricacies of Pharmacovigilance System Master File (PSMF) management and explore proven strategies to ensure inspection readiness, effective MAH oversight, and regulatory compliance...

Previous Webinar Arrow Next Webinar Arrow